Lars wrote:Opexa went to great lengths to highlight the fact that there was "over 90 % reduction" in the first phases. I can assure you that is how they achieved funding and willing recruits. I can also assure you that if there were any way to make that case now.....they would have.
Yes, Opexa highlighted the 90% reduction data from their previous studies. In the data that has been released so far for the IIb study they ONLY mention lesion volume AT BASELINE. You can assume, suppose, hypothesize a lot of things but to go from a statement concerning lesion volume at baseline to your assumption that lesion volumes increased for the Tovaxin arm is simply not valid with the information that we have in hand at this point. Also, whether the lesion volume increased or decreased has EVERYTHING to do with the number of lesions and lesion volume that the patient started with... that's how you come up with a percent change from start to finish. Although we all would love to have the information, at this point we have no data regarding changes in lesion volumes. Once those data are released THEN we can discuss the "reduction is reduction, increase is increase" topic.
My whole point here is that let's deal with the data that has actually been released and not go into a feeding frenzy on what we think is written between the lines. Yes there is a lot of information that they did not present. Given that the last people have only very recently finished up the IIb phase, my bet is that a lot of the data has not even been analyzed at this point. So, that certain data was not discussed does not necessarily indicate that it did not turn out in Opexa's favor. I'll point it out again that in a 15 minute presentation at a scientific meeting the general setup is to spend 3 to 5 minutes introducing your project and providing background information, closer 5 minutes for a new and complex treatment paradigm, 5 to 7 minutes presenting the current data and then 5 minutes for questions. So, it is just impossible to present all of the data in a fully explained version in this setting even if you have all of the data fully analyzed.